Geert DHaens
AmsterdamUMC · Amsterdamumc location AMC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Geert DHaens as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:05 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06188637 · Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ StudyGeert D'Haens · withdrawn · Ulcerative Colitis · principal investigator
- Ph4NCT03937609 · TITRATE (inducTIon for acuTe ulceRATivE Colitis)Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · terminated · Colitis, Ulcerative · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:05 UTC. The ranking covers the 200 most relevant of 206 PubMed records, and a shared surname and initials can bring in a namesake. All 206 on PubMed
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med · 20093,109 citationsRCR 73.8
- Infliximab, azathioprine, or combination therapy for Crohn's disease.N Engl J Med · 20102,624 citationsRCR 77.0
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.N Engl J Med · 20171,428 citationsRCR 54.8
- Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.Gastroenterology · 20121,055 citationsRCR 35.8
- 1,051 citationsRCR 30.1
- Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.Gastroenterology · 1999919 citationsRCR 24.2
- Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.Ann Intern Med · 2007810 citationsRCR 23.7
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.Lancet · 2017777 citationsRCR 35.3
- 741 citationsRCR 22.6
- Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis.Gastroenterology · 2015734 citationsRCR 25.7